Nebenwirkungen · Firazyr
Firazyr 30 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 6
HOS-209602 · Präparat HOS-154329
System Organ Class Preferred Term (incidence category) Nervous system disorders (Common, ≥ 1/100 to < 1/10) Dizziness Headache Gastrointestinal disorders (Common, ≥ 1/100 to < 1/10) Nausea Skin and subcutaneous tissue disorders (Common, ≥ 1/100 to < 1/10) Rash Erythema Pruritus (Unknown) Urticaria General disorders and administration site conditions (Very Common, ≥ 1/10) Injection site reactions* (Common, ≥ 1/100 to < 1/10) Pyrexia Investigations (Common, ≥ 1/100 to < 1/10) Transaminases increased * Injection site bruising, Injection site hematoma, Injection site burning, Injection site erythema, Injection site hypoesthesia, Injection site irritation, Injection site numbness, Injection site edema, Injection site pain, Injection site pressure sensation, Injection site pruritus, Injection site swelling, Injection site urticaria, and Injection site warmth.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-01T14:46:00Z · SHA-256 27aefe1246e8a2cb0ddef4ddfd0cc038053c091e5bdbdb7df21b3dd3829228de · Passage a1c778506ca7ec4a3b077fdcb5b86a5158d525eb53b4acb01a6ae068f0defda9 · Zeichen 1121–2791 im Abschnitt